论文部分内容阅读
目的:探讨应用洛赛克联合立止血治疗应激性溃疡出血的临床疗效。方法:70例应激性溃疡出血患者随机分为治疗组(n=35),对照组(n=35)。所有患者给予补液、抗休克及相应病因治疗外,治疗组给予洛赛克40mg静脉推注,每隔12h1次;立止血1KU静脉推注,每隔12h1次,对照组仅给予洛赛克40mg静脉推注,每隔12h1次。结果:治疗组临床疗效显著优于对照组(P<0.05)。结论:洛赛克联合立止血治疗应激性溃疡出血的临床疗效较单纯运用洛赛克更为有效、持久。
Objective: To investigate the clinical efficacy of Losec combined with Rituximab for the treatment of stress ulcer bleeding. Methods: Seventy patients with stress ulcer bleeding were randomly divided into treatment group (n = 35) and control group (n = 35). All patients were given rehydration, anti-shock and the corresponding cause of treatment, the treatment group were given intravenous injection of 40mg Losec, every 12h1 times; stop bleeding 1KU intravenous injection, every 12h1 times, the control group was given only 40mg Losec vein Push, every 12h1 times. Results: The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). Conclusion: The clinical efficacy of Losec combined with Rituximab for the treatment of stress ulcer bleeding is more effective and durable than that of Losec alone.